drugset / Trial / NCT02633813
BE Study of Naftifine HCL
RandomizedParallel-groupDouble-blindTreatment
Summary
The current study was randomized, double blind, placebo-controlled, prospective, multicenter, comparative therapeutic equivalence study. The study duration for each patient was 6 weeks: Following were the visit details. V1-Baseline and Randomization Visit (Day 1). V2- End of therapy visit (at the end of week 2 + 2 days). V3- Follow up visit (at the end of week 4 + 2 days). V4 - Test of cure visit ( at the end of week 6 + 4 days).
Timeline
- Start
- 2015-03
- Primary completion
- 2015-11
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naftifine | Other / unclassified | 2 % | Topical |